SYRS - Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
- Syros Pharmaceuticals ( NASDAQ: SYRS ) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer.
- SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement .
- The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition.
- SYRS stock +4.5% to $0.80 after hours.
For further details see:
Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609